Tower Research Capital (TRC)
AKCA

Tower Research Capital (TRC)’s Akcea Therapeutics Inc AKCA Stock Holding History

Tower Research Capital (TRC)’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,876
Closed -$143K – 5640
2020
Q3 		$143K Buy
7,876
+3,704
+89% +$52.5K ﹤0.01% 2864
2020
Q2 		$57K Buy
4,172
+4,072
+4,072% +$62.8K ﹤0.01% 2956
2020
Q1 		$1K Sell
100
-9,572
-99% -$157K ﹤0.01% 2926
2019
Q4 		$164K Buy
+9,672
New +$180K 0.01% 675
2019
Q2 		– Sell
-200
Closed -$6K – 4627
2019
Q1 		$6K Buy
200
+102
+104% +$2.97K ﹤0.01% 3011
2018
Q4 		$3K Buy
+98
New +$2.75K ﹤0.01% 3274
2018
Q3 		– Sell
-3,477
Closed -$82K – 4478
2018
Q2 		$82K Buy
3,477
+1,882
+118% +$44.9K ﹤0.01% 1563
2018
Q1 		$41K Sell
1,595
-2,278
-59% -$49K ﹤0.01% 1790
2017
Q4 		$67K Sell
3,873
-3,181
-45% -$62.4K 0.01% 1122
2017
Q3 		$195K Buy
+7,054
New +$131K 0.02% 791

Tower Research Capital (TRC)'s AKCA Position: Q4 2020 in Review

Tower Research Capital (TRC) sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 7,876 shares — an estimated $143K sold.

Tower Research Capital (TRC) first reported a position in AKCA in Q3 2017 and held it in 10 quarters. The position peaked at $195K in Q3 2017. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Tower Research Capital (TRC) reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7,876 Akcea Therapeutics Inc shares in Q4 2020, an estimated $143K.
  • Tower Research Capital (TRC) first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Akcea Therapeutics Inc position peaked at $195K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2020, filed 16 Feb 2021.